Volume : 12, Issue : 10, October – 2025
Title:
PHARMACOLOGICAL EVALUATION OF OXYSTELMA ESCULENTUM EXTRACT ON ALZHEIMERS DISEASE IN MICE
Authors :
Bammidi Vidyasagar , V. Devi, Dr.M.B.V.Raju
Abstract :
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory impairment and cognitive decline. In this study, the anti-Alzheimer’s potential of Oxystelma esculentum R.Br. was investigated using in vitro and in vivo models. Sequential extraction of the aerial parts of the plant was performed using hexane, chloroform, ethyl acetate, and ethanol. Phytochemical analysis revealed that the ethanolic extract contained glycosides, flavonoids, phytosterols, alkaloids, terpenoids, and phenolic compounds, indicating its rich bioactive profile.
The acetylcholinesterase inhibition assay demonstrated significant in vitro activity, with the ethanolic extract showing the lowest IC50 value (38.54 µg/mL) compared to other extracts, suggesting potential to enhance cholinergic neurotransmission. Acute toxicity studies in Swiss albino mice indicated the ethanolic extract was safe up to 2000 mg/kg body weight, with no mortality or significant behavioral changes observed.
In vivo evaluation using scopolamine-induced amnesia in mice demonstrated that oral administration of ethanolic extract (200 and 400 mg/kg) significantly improved memory and learning, as evidenced by Y-maze, open-field, and traction tests. Biochemical assessments revealed a reduction in malondialdehyde (MDA) levels and enhancement of antioxidant enzymes such as catalase and glutathione, indicating a protective effect against oxidative stress.
The findings suggest that the ethanolic extract of O. esculentum exhibits neuroprotective activity and may ameliorate cognitive deficits, potentially through cholinesterase inhibition and antioxidant mechanisms. These results support the traditional use of the plant in managing memory disorders and highlight its potential as a source of therapeutic agents for Alzheimer’s disease.
Keywords
Oxystelma esculentum, Alzheimer’s disease, Acetylcholinesterase inhibition, Phytochemicals, Ethanol extract, Neuroprotection, Oxidative stress, Scopolamine-induced amnesia, Memory enhancement, Antioxidant enzymes
Cite This Article:
Please cite this article in press Bammidi Vidyasagar et al., Pharmacological Evaluation Of Oxystelma Esculentum Extract On Alzheimers Disease In Mice, Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1. Breijyeh, Z., & Karaman, R. (2020). Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules, 25(24), 5789. https://doi.org/10.3390/molecules25245789
2. Felson, S., MD. (2020, July 31). Dementia and Alzheimer’s guide: Types of Alzheimer’s disease.
3. Kumar, A., Singhal, V., & Naithani, V. (2022). Medicinal plants with potential to treat Alzheimer’s and associated symptoms. International Journal of Neuropsychopharmacology and Nutrition Disorders. Retrieved from http://www.ijnpnd.com
4. Hölscher, C. (1998). Possible causes of Alzheimer’s disease: Amyloid fragments, free radicals, and calcium homeostasis. Neurobiology of Disease, 5(3), 129–141. https://doi.org/10.1006/nbdi.1998.0193
5. Drugwatch. (n.d.). Progression of Alzheimer’s disease. Retrieved from https://www.drugwatch.com/wp-content/uploads/progression-alzheimers-disease.png
6. Britannica. (n.d.). Neuron network with amyloid plaques. Retrieved from https://cdn.britannica.com/77/190277-050-F6CFBF07/neuron-network-amyloid-plaques.jpg
7. Science. (2021). Alzheimer’s gene study. Retrieved from https://www.science.org/do/10.1126/science.acx9319/full/_20211007_on_alzheimersgene.jp
8. Francis, P. T. (2005). The interplay of neurotransmitters in Alzheimer’s disease. CNS Spectrums, 10(11 Suppl 18), 6–9. https://doi.org/10.1017/s1092852900014164
9. Felson, S., MD. (2020, July 31). Dementia and Alzheimer’s guide: Types of Alzheimer’s disease.
10. Mueller, S. G., Weiner, M. W., Thal, L. J., & Petersen, R. C. (2005). Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI). Journal of Alzheimer’s Disease, 1(1), 55–66.
11. Wilkinson, D. G., Francis, P. T., Schwam, E., & Payne-Parrish, J. (2004). Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: The relationship between pharmacological effects and clinical efficacy. Drugs & Aging, 21(7), 453–478. https://doi.org/10.2165/00002512-200421070-00004
12. Tadvi, N. (2011). Drug treatment for Alzheimer’s disease [Slideshare].
13. Akram, M., & Nawaz, A. (2017). Effects of medicinal plants on Alzheimer’s disease and memory deficits. Neural Regeneration Research, 12(4), 660–670. https://doi.org/10.4103/1673-5374.205108
14. Sasidharan, S., et al. (2011). Extraction, isolation and characterization of bioactive compounds from plant extracts. African Journal of Traditional, Complementary, and Alternative Medicines (AJTCAM), 8(1), 1–10.
15. Vectorstock. (n.d.). Collection of herbs for Alzheimer’s disease [Image]. Retrieved from https://cdn.vectorstock.com/i/1000×1000/89/21/collection-of-herbs-for-alzheimer-disease-vector-13808921.webp
16. Natarajan, S., Shanmugiahthevar, K. P., & Kasi, P. D. (2009). Cholinesterase inhibitors from Sargassum and Gracilaria gracilis: Seaweeds inhabiting South Indian coastal areas (Hare Island, Gulf of Mannar). Natural Product Research, 23, 355–369.
17. Apostolova, L. G. (2016). Alzheimer disease. In Dementia (pp. 419–434). Vol. 22, No. 2. https://doi.org/10.1212/CON.0000000000000307